Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform
Selexis SA and Berkeley Lights, Inc. today announced a collaboration around the acquisition of Berkeley Lights’ Beacon® optofluidic platform. The partners will leverage the technology to accelerate cell line development (CLD) with the Selexis SUREtechnology Platform™. Selexis scientists have extensively evaluated the Beacon technology and will now further incorporate it into the SUREtechnology Platform workflow. Utilizing the Beacon’s optofluidic and single cell analysis technology, the Selexis team has significantly shortened the time required to identify and select the optimal cell line manufacturing clones within the CLD process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005414/en/
“We are very enthusiastic about the timeline advantages that the Beacon platform will bring to our SUREtechnology Platform,” said Igor Fisch, PhD, chief executive officer of Selexis. “This optofluidic technology helps us continually improve and accelerate cell line development. Our client partners consider every month of lead time ahead of a competitor to be a significant advantage. We believe we will be able to give our partners a strong first-in-human (FIH) and first-to-market (FTM) head start while helping them deliver much-needed medicines to patients.”
Selexis’ SUREtechnology Platform is based upon optimized epigenetic DNA-based elements (Selexis Genetic Elements) that protect integrated transgenes from the transcription silencing effects of surrounding chromatin, allowing for robust production levels of protein therapeutics. This technology eliminates the need for large-scale screening to identify high-producing clones; allowing for research cell bank generation in as little as 14 weeks. Of that 14-week development time, subcloning and optimal clone identification still typically require four to eight weeks. By integrating the Beacon technology into the SUREtechnology Platform and by adapting a unique and proprietary cell clone prediction tool, the Company will be able to shave off several weeks in the development of a research cell bank, thereby speeding the development of high-quality drug product to the clinic.
“We are very pleased to be working with Selexis and value our collaboration that led to the optimization of the Beacon platform for use with the SUREtechnology Platform,” said Andy Last, PhD, chief commercial officer, at Berkeley Lights, Inc. “We are quite proud of the success of the Beacon platform in providing unparalleled single cell analytic and isolation technologies to accommodate the breadth of needs across the cell line development field.”
About Selexis SA
Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of three commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com.
About Berkeley Lights
Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell-based products and therapies. At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows. Each workflow provides a 100-fold increase in insights, 10 times faster, at a fraction of the cost.
FOR MORE INFORMATION
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005414/en/